Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates... see more

Recent & Breaking News (NDAQ:INCY)

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Business Wire October 3, 2022

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement

Business Wire August 26, 2022

Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress

Business Wire August 24, 2022

Incyte to Present at Upcoming Investor Conference

Business Wire August 23, 2022

Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Business Wire August 2, 2022

Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo

Business Wire July 18, 2022

Incyte to Report Second Quarter Financial Results

Business Wire July 12, 2022

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata

PR Newswire June 13, 2022

Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting

Business Wire May 26, 2022

Incyte to Present at Upcoming Investor Conference

Business Wire May 24, 2022

CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)

PR Newswire May 20, 2022

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

PR Newswire May 11, 2022

Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Business Wire May 5, 2022

Incyte to Present at Upcoming Investor Conference

Business Wire May 4, 2022

Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Business Wire May 3, 2022

Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan

Business Wire April 28, 2022

Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer

Business Wire April 22, 2022

Incyte to Report First Quarter Financial Results

Business Wire April 12, 2022

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies

PR Newswire March 26, 2022

Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura(TM)) in Patients With Vitiligo

Business Wire March 26, 2022